Showing 1 - 2 of 2
Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a...
Persistent link: https://www.econbiz.de/10011471556
Objectives: To estimate the cost savings and health benefits in the UK NHS that could be achieved if human milk usage in the NICU was increased. Methods: A systematic review established the disease areas with the strong sources of evidence of the short, medium and long-term benefits of human...
Persistent link: https://www.econbiz.de/10011587181